Press Release

Boston Harbor Angels Celebrates 20 Years of Angel Investing

  Boston, MA – March 15th, 2024 – Boston Harbor Angels (BHA) proudly commemorates two decades of catalyzing innovation and fostering entrepreneurial growth within the Boston ecosystem. Since its inception, BHA has supported countless startups and contributed significantly to the economic development of New England and beyond. Founded in 2004, Boston Harbor Angels strives to be at the forefront of angel investing, providing vital funding and mentorship to emerging companies across various industries such as life sciences, information technology, and many more. ...
Read more...

Boston Harbor Angels to Expand to Miami

Boston Harbor Angels to Expand to Miami January 18, 2022, Boston, MA: Boston Harbor Angels, Inc (BHA), a leading Boston-based angel investment group, announced today that it is opening a Miami presence of BHA. Ziad Moukheiber, President and CEO of BHA said, “We are very excited to have a presence in Miami and to collaborate with local investors and entrepreneurs to continue the BHA brand of investing for a better world.” BHA will extend its long and fruitful collaboration with Babson College...
Read more...

Boston Harbor Angels Brings Equity Venture Partners as New Sponsor

Boston Harbor Angels, one of the top three elite angels groups in the US, is pleased to announce that Equity Venture Partners has joined as a new sponsor. About Equity Venture Partners Equity Venture Partners (www.equityvp.com) provides fee simple ownership in Class A & B commercial real estate investment opportunities nationwide to accredited investors with a focus on attaining the greatest risk-adjusted rate of return. We act as the General Partner on all EVP investments and unlike many other firms that sponsor...
Read more...

Boston Harbor Angels Awards Portfolio Companies at Annual Meeting

Boston Harbor Angels, one of the top three elite angels groups in the US, recognized three portfolio companies at its annual end-of-year general meeting. Exit of the Year Award: Corbus Pharmaceuticals on NASDAQ Biotech Startup of the Year Award: Astrocytes Pharmaceuticals Inc. IT Startup of the Year Award: Wasabi The meeting featured interviews with Yuval Cohen, CEO of Corbus Pharmaceuticals and Mark Tepper, President & Chief Scientific Officer of Corbus Pharmaceuticals; and David Friend, CEO and co-founder of Wasabi. The group also honored Mic Williams,...
Read more...

Boston Harbor Angels Sponsors Babson’s Summer Venture Showcase

Boston Harbor Angels, one of the top three elite angels groups in the US, is proud to sponsor Babson College's Summer Venture Showcase. This Babson signature event will be hosted at The Federal Reserve Bank of Boston on Thursday, July 27, 2017. The summer accelerator of the Arthur M. Blank Center for Entrepreneurship, the Summer Venture Program is a 10-week intensive experience designed to accelerate the development of student entrepreneurial ventures. The program supports the most promising graduate and undergraduate entrepreneurs...
Read more...

Boston Harbor Angels Hosts Gavea Angels of Brazil

Boston Harbor Angels, one of the top three elite angels groups in the US, will be hosting Brazilian angel group Gavea Angels on Thursday, April 6, 2017. Gavea Angels, a leading Brazilian angel investment group, has organized a "Investor’s Week in Boston" to promote and establish connections between the angel communities in Brazil and the US. In addition to the Boston Harbor Angels, Gavea Angels will also visit universities such as Harvard and MIT, the Cambridge Innovation Center and MassChallenge. About...
Read more...

Boston Harbor Angels Bet on New Frontier in Neuroscience

Boston Harbor Angels has invested in two neuroscience startups targeting stroke, TBI and Parkinson's Disease, leading a $1.3M angel seed round in Astrocyte Pharmaceuticals and members investing in Neuraly. Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke, TBI, concussion, and neurodegenerative disorders such...
Read more...